23andMe (ME)
Search documents
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
GlobeNewswire News Room· 2024-07-25 11:30
Sobering lung cancer statistics only tell part of the story Despite advances in treatment options, lung cancer remains a critical area of unmet need: Behind every devastating statistic are people from communities across the U.S. impacted by lung cancer. Through this collaboration, advocacy organizations, lung cancer survivors and advocates, and 23andMe hope ultimately to help advance research toward finding a cure for this disease. "Studying the genetics of lung cancer can help us understand risks, improve ...
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
Newsfilter· 2024-06-28 11:00
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health's clinicallyvalidated and cost-effective blood metabolomics panel with a cohort of 23andMe members. 23andMe currently offers its annual members the option for blood testing and provides interactive tools like He ...
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
GlobeNewswire News Room· 2024-06-28 11:00
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health's clinicallyvalidated and cost-effective blood metabolomics panel with a cohort of 23andMe members. Nightingale's Remote Health Check accurately measures dozens of biomarkers from a single blood sample, includin ...
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Investor Place· 2024-06-11 10:00
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable. However, despite their low prices, these stocks are often the riskiest to own. Many are still in the process of establishing themselves in their respective markets or lack a solid foundation for significant growth. That said, there are exceptions. These three penny stocks are loaded with growth potential and have exciting developments c ...
UK and Canada privacy watchdogs investigating 23andMe data breach
TechCrunch· 2024-06-10 15:11
On Monday, the U.K,'s Information Commissioner's Office (ICO) and the Office of the Privacy Commissioner of Canada (OPC) announced their investigation into the genetic testing company, saying the organizations will leverage "the combined resources and expertise of their two offices." "This data breach had an international impact, and we look forward to collaborating with our Canadian counterparts to ensure the personal information of people in the U.K. is protected," said Edwards. Hackers broke into around ...
23andMe Launches New Genetic Report on Bipolar Disorder
Newsfilter· 2024-06-05 11:00
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to ...
Why 23andMe Stock Tumbled 10% on Tuesday
The Motley Fool· 2024-06-04 16:48
Is altruism a good idea for an unprofitable capitalistic enterprise? Genetic database builder 23andMe (ME -11.45%) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal Cancer Alliance "to help advance research on colorectal cancer in the Black/African American community." Now, why might investors consider this bad news for 23andMe stock? Non-profit plus ...
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
Newsfilter· 2024-06-04 11:00
SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community. The Genetic Insights into Colorectal Cancer in the Black Community Study is part of 23andMe's continued efforts to raise aware ...
23andMe (ME) - 2024 Q4 - Annual Report
2024-05-30 20:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ______________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM___________ TO___________ Commission File Number 001-39587 ___________________________________________ ...
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
globenewswire.com· 2024-05-29 12:00
The LRRK2 variant is strongly associated with symptoms of Parkinson's disease (PD) that are different from non-variant carriers with the disease The study revealed novel findings of genetic "hotspots" in people from Mexico, Cuba, Puerto Rico, and Brazil, where the founder variant has sprung up in other communities 23andMe has the largest LRRK2 G2019S research cohort, and launched the Parkinson's Impact Project (PIP) in 2018 to better understand which carriers are at greater risk of developing Parkinson's di ...